Hirschl M M, Heinz G, Sunder-Plassmann G, Derfler K
Department of Emergency Medicine, New General Hospital, University of Vienna, Austria.
Am J Kidney Dis. 1992 Dec;20(6):564-8. doi: 10.1016/s0272-6386(12)70219-6.
The objective of this study was to determine the impact of renal transplantation and hemodialysis treatment on outcome of elderly diabetic patients with end-stage renal disease (ESRD) among other factors related to survival. Results of treatment of ESRD in 78 patients with non-insulin-dependent diabetes mellitus (type 2) showed a survival rate of 58% at 1 year and 14% at 5 years, independent of treatment modality. Patients who received a renal allograft had a higher survival rate as compared with patients on hemodialysis treatment (5-year survival, 59% v 2%; P < 0.005). Diabetic patients with a history of myocardial infarction, stroke, or peripheral gangrene before onset of renal replacement therapy had a worse prognosis in comparison to patients without vascular complications (5-year survival, 2% v 21%; P < 0.05). Analysis of patients who survived less than 6 months and more than 24 months was performed. Long-term survivors were slightly younger, had diabetes for a shorter period, and showed a better metabolic control of diabetes mellitus. Sixteen long-term survivors received a renal allograft. In contrast, only three short-term survivors were transplanted. Furthermore, short-term survivors also had a greater than 70% incidence of severe vascular complications before renal replacement therapy. A history of myocardial infarction, stroke, or peripheral gangrene is an independent predictor of decreased survival, irrespective of whether the patients were transplanted or maintained on chronic hemodialysis treatment. In contrast, renal transplantation improved survival of elderly diabetic patients without vascular complications and should be the treatment of choice in this specific group of patients.
本研究的目的是确定肾移植和血液透析治疗对老年终末期肾病(ESRD)糖尿病患者预后的影响,以及其他与生存相关的因素。78例非胰岛素依赖型糖尿病(2型)ESRD患者的治疗结果显示,1年生存率为58%,5年生存率为14%,与治疗方式无关。接受同种异体肾移植的患者与接受血液透析治疗的患者相比,生存率更高(5年生存率,59%对2%;P<0.005)。与无血管并发症的患者相比,在开始肾脏替代治疗前有心肌梗死、中风或外周坏疽病史的糖尿病患者预后更差(5年生存率,2%对21%;P<0.05)。对存活时间少于6个月和超过24个月的患者进行了分析。长期存活者年龄稍小,患糖尿病时间较短,糖尿病代谢控制较好。16例长期存活者接受了同种异体肾移植。相比之下,只有3例短期存活者接受了移植。此外,短期存活者在肾脏替代治疗前严重血管并发症的发生率也超过70%。心肌梗死、中风或外周坏疽病史是生存率降低的独立预测因素,无论患者是接受移植还是维持慢性血液透析治疗。相比之下,肾移植提高了无血管并发症的老年糖尿病患者的生存率,应该是这一特定患者群体的首选治疗方法。